An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

Summary

This Phase 2, multi-center, double-blind, randomized, placebo-controlled, parallel group, add-on study of MLR 1023 in adults with uncontrolled T2DM on metformin anti diabetic monotherapy is designed to evaluate the efficacy and safety of MLR 1023 in combination with metformin in subjects with uncontrolled T2DM.

Timeline

Start

2017-09-01

Primary completion

2019-09

Completion

2019-09

Outcome

Met primary endpoint

release “MLR-1023은 다국가 전기2상 임상시험에서 1차 유효성 평가변수인 혼합 식사 내성 검사를 통해 측정한 식후 혈당 감소량 (MMTT)을 측정한 결과, 혈당 감소효과를 보였으며” bukwang.co.kr ↗

Drugs

Indications